Madison Dialysis, Llc is a medicare approved dialysis facility center in Austin, Texas and it has 12 dialysis stations. It is located in Travis county at 11150 Research Blvd., Austin, TX, 78759. You can reach out to the office of Madison Dialysis, Llc at (512) 342-1097. This dialysis clinic is managed and/or owned by Davita. Madison Dialysis, Llc has the following ownership type - Profit. It was first certified by medicare in September, 2017. The medicare id for this facility is 672824 and it accepts patients under medicare ESRD program.
Name | Madison Dialysis, Llc |
---|---|
Location | 11150 Research Blvd., Austin, Texas |
No. of Dialysis Stations | 12 |
Medicare ID | 672824 |
Managed By | Davita |
Ownership Type | Profit |
Late Shifts | No |
11150 Research Blvd., Austin, Texas, 78759 | |
(512) 342-1097 | |
Not Available |
News Archive
Cancer Research UK, the world's leading charity dedicated to cancer research, is celebrating after the launch of its new two-year partnership with Network Rail got off to a flying start, raising almost £200,000 in the first three months of the partnership.
The presence of bacteremia in patients with pneumonia is associated with a worse in-hospital course of illness and poorer patient outcomes, show Spanish findings.
In two articles, published in Circulation, researchers from the University of Pennsylvania School of Medicine provide further evidence for the role of cyclooxygenases (COX) in heart-disease risk.
Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patents listed by Abbott Laboratories in connection with its TRICOR® (fenofibrate) tablets, 48 mg and 145 mg.
› Verified 3 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
Adult patients getting regular hemodialysis at the center | 3 |
Adult patient months included in Kt/V greater than or equal to 1.2 | 27 |
Percentage of adult patients getting regular hemodialysis at the center | |
Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Cancer Research UK, the world's leading charity dedicated to cancer research, is celebrating after the launch of its new two-year partnership with Network Rail got off to a flying start, raising almost £200,000 in the first three months of the partnership.
The presence of bacteremia in patients with pneumonia is associated with a worse in-hospital course of illness and poorer patient outcomes, show Spanish findings.
In two articles, published in Circulation, researchers from the University of Pennsylvania School of Medicine provide further evidence for the role of cyclooxygenases (COX) in heart-disease risk.
Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patents listed by Abbott Laboratories in connection with its TRICOR® (fenofibrate) tablets, 48 mg and 145 mg.
› Verified 3 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Madison Dialysis, Llc with elevated calcium levels.
Patients with hypercalcemia | 3 |
Hypercalcemia patient months | 27 |
Hypercalcemia patients with serumcalcium greater than 10.2 mg | |
Patients with Serumphosphor | 3 |
Patients with Serumphosphor less than 3.5 mg/dL | |
Patients with Serumphosphor from 3.5 to 4.5 mg/dL | |
Patients with Serumphosphor from 4.6 to 5.5 mg/dL | |
Patients with Serumphosphor from 5.6 to 7 mg/dL | |
Patients with Serumphosphor greater than 7 mg/dL |
News Archive
Cancer Research UK, the world's leading charity dedicated to cancer research, is celebrating after the launch of its new two-year partnership with Network Rail got off to a flying start, raising almost £200,000 in the first three months of the partnership.
The presence of bacteremia in patients with pneumonia is associated with a worse in-hospital course of illness and poorer patient outcomes, show Spanish findings.
In two articles, published in Circulation, researchers from the University of Pennsylvania School of Medicine provide further evidence for the role of cyclooxygenases (COX) in heart-disease risk.
Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patents listed by Abbott Laboratories in connection with its TRICOR® (fenofibrate) tablets, 48 mg and 145 mg.
› Verified 3 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
Patients included in arterial venous fistula and catheter summaries | 1 |
Patient months included in arterial venous fistula and catheter summaries | 1 |
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | |
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer |
News Archive
Cancer Research UK, the world's leading charity dedicated to cancer research, is celebrating after the launch of its new two-year partnership with Network Rail got off to a flying start, raising almost £200,000 in the first three months of the partnership.
The presence of bacteremia in patients with pneumonia is associated with a worse in-hospital course of illness and poorer patient outcomes, show Spanish findings.
In two articles, published in Circulation, researchers from the University of Pennsylvania School of Medicine provide further evidence for the role of cyclooxygenases (COX) in heart-disease risk.
Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patents listed by Abbott Laboratories in connection with its TRICOR® (fenofibrate) tablets, 48 mg and 145 mg.
› Verified 3 days ago